Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Juli...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched its M...
Sanofi is all in on AI and wants to become the first biopharma company powered by AI at scale. The company is using AI to chase the miracles of science b...
HealthTech Bioactives (HTBA) the leading innovator in polyphenol and vitamin B12 solutions for human and animal health and nutrition, is pleased to annou...
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-m...
YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A fina...
The life science group Sartorius is expanding its multidisciplinary collaboration with NVIDIA to help enable the development of new and better therapies, c...
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of bett...
Bruker Corporation announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European ...
QIAGEN announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for i...
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced the launch of Epidemiology Intelligence™. The new sol...
KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a le...
BBI Solutions OEM Limited (BBI), a trusted expert provider of end-to-end solutions for the development of high-performance assays, has signed a partnership...
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by...
© 2025 Biopharma Boardroom. All Rights Reserved.
